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Polymorphism is  a  relatively  common phenomenon  among pharmaceutical  compounds,  and  one  of  the  main  aspects  to  be
considered in the production and development of medications. The investigation of polymorphism associated with oxicams, a
group belonging to the class of non-steroidal anti-inflammatory drugs (NSAIDs) has increased in recent years and, in the case of
tenoxicam, the existence of four polymorphic forms is reported in the literature. The objective of this study was to characterize the
presence of different polymorphic forms of tenoxicam in active pharmaceutical ingredient and oral pharmaceutical formulations,
as well as to evaluate the influence on in vitro dissolution. The characterization of the three samples of pharmaceutical ingredient
of tenoxicam from different suppliers by X-Ray Diffraction (XRD), Infrared (IR) and dissolution profile indicated the presence of
a form III crystalline structure, without presenting significant differences between the in vitro dissolution profiles analyzed, and a
Dissolution  Efficiency  (DE%)  of  60.30%,  60.70%  and  72.34%,  respectively.  When  the  four  pharmaceutical  specialties  of
tenoxicam were submitted to XRD analysis, they also presented form III crystalline structures. Despite this, the formulations
presented different dissolution profiles and a DE% of 75.23%, 83.69%, 78.19% and 90.63%, respectively, without compromising
their quality. However, often polymorphism affects physico-chemical properties of drugs, showing the importance of studying this
phenomenon,  by  correlating  the  presence  of  crystalline  structures  to  alterations  in  the  quality  of  active  ingredients  and
pharmaceutical products.
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Introduction 
Polymorphism  is  a  frequent  phenomenon  among
pharmaceutical compounds, and one of the main aspects to
be  considered  in  the  production  and  development  of
medications.  Its  presence  may  impair  the  health  of  the
population  and  have  a  strong  economic  impact  on  the
pharmaceutical  industries.  According  to  the  polymorph
involved in the production, the medication may present as
less  active,  active  or  toxic  to  the  human  organism  (1,2).
It  is  decisively  important  to  understand  the  relationship
between crystalline material  and its  properties  in  order  to
select the most appropriate polymorph for the development
of a pharmaceutical  specialty.  Polymorphism may directly
influence the mechanical properties of active pharmaceutical
ingredient such as flux, elasticity, compressibility and force
of  bonding,  and  also  the  bioavailability  of  the
pharmaceutical product (3,4). Moreover, changes may occur
in  the  crystalline  structure  resulting  from  the  industrial
production process, reinforcing the importance of studying
polymorphic behavior involving finished products (5,6).
Transformations  induced  by  processing  during  the
production  of  pharmaceutical  products  are  difficult  to
predict  and  control.  Subjecting  an  active pharmaceutical
ingredient  with  a  given  crystalline  structure  to  industrial
processing  may  induce  modifications  in  the  crystalline
phase.  The  milling  process  may  generate  significant
amounts of heat, consequently generating transformations of
the  crystalline  phase  and  amorphous  components.  Wet
granulation  also  provides  an  ideal  environment  for  the
crystallization of new crystalline phases, as it involves the
mixture  of  the  active  ingredient  and  excipients  with  a
granulation liquid, and also requires the product to be dried
and  milled  (7,8). 
Polymorphism  may  affect  various  pharmaceutical  classes
including the oxicam group. This group belongs to the class
of  Non-Steroidal  Anti-inflammatory  Drugs  (NSAIDs)  (9).
The investigation of  polymorphism associated with oxicams
has  increased  in  recent  years  (10),  and  data  from  the
literature  report  the  existence  of  four  polymorphic  forms
(forms  I, II, III and IV) for tenoxicam (11). It is therefore
relevant to perform tests that will characterize the solid state
of  this  drug  aiming  to  analyze  the  quality  parameters  of
active  pharmaceutical  ingredient and  finished  products,
since the possibility of polymorphism is a critical factor for
the  pharmaceutical  industries.  Therefore,  the  objective  of
this  study  was  to  evaluate  the  crystalline  structure  and
influence on the in vitro dissolution profile of tenoxicam in
active  pharmaceutical  ingredient and  oral  pharmaceutical
formulations available in the consumer market.
27
Drug Anal Res, 2018; 02, 27-36
Material and Methods
Reference standard
The standard used was compound 4-hydroxy-2-methyl-N-2-
pyrimidilo-2H-thiene  [2,3-e]  -1,2-thiazine-3-carboxamide-
1,1-dioxide  (tenoxicam)  obtained  from Changzhou  Hubin
Medicine Raw Materials Co. Ltd (Changzhou, China), with
a declared content of 99.59%. 
Samples
Three  samples  of  active  pharmaceutical  ingredient  of
tenoxicam  (GTE1,  STE2  and  NTE3)  evaluated  were
acquired  from the following pharmacochemical  industries:
Glenmark  Generics  Ltd.  (Daund,  India),  Sifovitor  Infa
Group  S.p.A.  (Casaletto  Lodigiano,  Italy)  and  Nantong
Jinhua  Pharmaceutical  Co.  Ltd (Nantong,  China),
respectively.  
Samples of pharmaceutical specialties (VTE0, RTE1, ETE2
and MTE3) containing tenoxicam at a concentration of 20
mg were obtained from Brazilian pharmaceutical industries.
The placebos were prepared in the laboratory based on the
composition  of  the  excipients  present  in  the  samples  of
tablets, namely, lactose, amide, talcum, magnesium stearate,
sodium  amidoglycolate,  hypromellose,  sodium
croscarmellose,  microcrystalline  cellulose,
hydroxypropylmethylcellulose,  ethylcellulose,  macrogol,
polyethylenoglycol,  titanium  dioxide,  silicon  dioxide,
tartrazine  yellow,  and  yellow  iron  oxide.  Monobasic
Potassium Phosphate (KH2PO4)  was obtained from Merck
(Darmstadt, Germany).
Tenoxican polymorphs
Tenoxicam polymorphs used were prepared according to the
procedures described in the literature (11) and the conditions
selected were as follows:
Preparation  of  form  I: Tenoxicam  was  dissolved  in
chloroform (Nuclear®, Lot 09111520) at 60 °C (30 mg/ml)
and then cooled at a temperature of 4 °C (ice bath). After six
days stored at room temperature it was filtrated.
Preparation  of  form  II: Tenoxicam was  dissolved  in
butanol  (Labsynth®,  Lot  114005)  at  room temperature (3
mg/ml) and kept in this condition for two days.  After  the
stipulated time, filtration was performed.
Preparation  of  form  III: Tenoxicam  was  dissolved  in
isopropylic  alcohol  (Tedia®,  Lot  903139)  at  room
temperature (2 mg/ml), it was cooled at 4 °C (ice bath) and
the content was isolated by filtration. 
Preparation  of  form  IV: Tenoxicam  was  dissolved  in
methanol  (Merck®,  Lot  1672807)  at  room temperature  (2
mg/ml) and left to rest in this state for two days. Filtration
was performed after the stipulated time.
Thermal Analyses
A  Shimadzu®  Differential  Scanning  Calorimeter  (Kyoto,
Japan),  model  DSC-60 with heat  flux and calibrated  with
indium (156.6 °C, transition energy -28.45 J/g-1)  and zinc
(419.58 °C, transition energy -100.50 J/g-1) was used. It was
equipped  with  a  FC-60A  flux  controller,  TA  60WS
integrator and control and analysis software TA 60 version
2.0.
The  DSC  curves  were  obtained  in  an  inert  nitrogen
atmosphere with a 50 ml/min flow and heating rate of 10 °C/
min beginning at 25 °C to 250 °C. Recrystallized samples of
tenoxicam (forms I, II, III and IV) ranging from 1.5 to 1.95
mg were placed on hermetic aluminium pans.
X-Ray Diffraction
The  Siemens® diffractometer,  model  D-5000  (Munich,
Germany) was used to analyze the samples. It was equipped
with Difrac® Plus EVA version 11.0 to identify and index
the  peaks  by  using  comparison  algorithms  based  on  the
JCPDS (Joint Committee on Power Diffraction Standards)
database. The analysis were performed at room temperature,
with samples in powder form, about 1 gram, using λCuCuKα
radiation (1.5409Å), that were scanned between 2 and 72°
(2θ), with speed of 0.02°/1s, using an energy of 40 kV and), with speed of 0.02°/1s, using an energy of 40 kV and
25 mA. The tablets submitted to the test were milled in an
agate  mortar.   
The  technique  was  performed  to  look  at  the  crystalline
structure present in the standard tenoxicam, in the crystalline
forms  prepared  (forms  I,  II,  III  and  IV),  in  the  active
pharmaceutical ingredient (GTE1, STE2 and NTE3) and in
the pharmaceutical tablets of the drug (VTE0, RTE1, ETE2
and MTE3).
Spectrophotometry by IV
The  absorption  spectrum  of  the  IV  region  was  obtained
using  a  Perkin  Elmer®  model  FT-IR  Spectrum  BX
Spectrophotometer (Massachusetts, USA) in the 600 to 4000
cm-1 range  with  a  scanning  number  of  100  scans.
Approximately 1 mg of powders from each sample was used
for analysis.
The  technique  was  used  to  identify  standard  tenoxicam,
evaluate  the  forms  I,  II,  III  and  IV  prepared,  and  to
characterize  the  active  pharmaceutical  ingredient  of
tenoxicam (GTE1, STE2 and NTE3).
Dissolution Profile
The procedure involved the use of the Varian® dissolution
apparatus (California, USA) model VK 7010 equipped with
6  vessels,  multiple  automatic  sampler  controlled  by  an
automatic station model  VK 8000, bidirectional  peristaltic
pump,  model  VK,  and  digital  heater/circulator  model  VK
750D. The experimental conditions were according to those
favored by the British Pharmacopoeia  (12).  To perform the
test  apparatus  2  (paddles)  were  used  with  an  agitation
velocity of 50 rpm, vessels containing 900 ml of monobasic
potassium phosphate pH 6.8 as a dissolution medium at a
temperature of 37 °C ± 0.5 °C. 
In order  to evaluate  the  in vitro dissolution profile of the
tenoxicam tablets (VTE0, RTE1, ETE2 and MTE3), 10 ml
aliquots were removed from each of the vessels, adequately
filtered with 0.45 µm filters at times of  2, 5, 10, 20 and 25
minutes. For the active pharmaceutical  ingredients (GTE1,
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STE2  and  NTE3)  evaluated,  20.0  mg  of  sample  were
weighed and 10 ml aliquots were removed from each of the
vessels, adequately, filtered with 0.45 µm filters at times of
5, 10, 15, 20, 25, 30, 35, 40, 45 and 50 minutes. 
The  absorption  spectrum  in  the  UV region  was  obtained
using  a  Shimadzu® spectrophotometer  (Kyoto,  Japan),
model  UV-1800,  equipped  with  quartz  cuvettes,  with  an
optical path of 1.0 cm and UV Probe software, version 2.33
to process  the data.  The amount of drug released into the
dissolution medium was determined at a wavelength of 368
nm.
The results of the dissolution profiles were evaluated by the
independent  model  method,  calculating  factors  f1  and f2,
and  by  the  dependent  model  method  using  mathematical
equations referring to zero order and first order. Dependent
models  were  applied  using  Micromath  Scientist  for
Windows software Version 2.01. Other parameters used to
characterize the dissolution profile  were the half life time
(t50%), amount released from the drug in 25 minutes (Q20) and
dissolution efficiency (DE%).
Results and discussion
Differential Scanning Calorimetry (DSC)
Tenoxicam polymorphs preparations 
The  DSC  curves  obtained  for  different  recrystallization
conditions of tenoxicam did not present significant changes
compared to the DSC data expected for the drug (Figure 1),
which presents an endothermic peak (fusion) close to 215.41
°C, followed by a an exothermic peak (degradation) (13). 
Figure 1. Thermal profile of recrystallized samples of tenoxicam in
a  nitrogen  atmosphere  of  50  ml/min  with  a  heating  rate  of  10
°C/min,  using  a  Shimadzu® Differential  Scanning  Calorimeter
model DSC-60.
Thus, no atypical event was observed in the samples (Figure
3),  because  they all  presented  an endothermic event  (heat
absorption), close to the original fusion range of tenoxicam
located between 209 °C and 213 °C (14).
When the polymorphism is present, the DSC curves have a
number  of  fusion  peaks  characteristic  of  the  crystalline
forms  present,  and  also,  thermal  events  such  as
decomposition and recrystallization are often observed when
DSC is used to characterize polymorphs (6,4). 
A single tenoxicam polymorphic form obtained (form III) is
related to its molecular shape, considering its low flexibility
(a factor which reduces the tendency to crystallization) and
the chemical bonds present in the molecule (Van der Waals
Forces, Dipole-Dipole and Hydrogen Bridges), that directly
influence  the  recrystallization  process.  The  intermolecular
forces influence the molecular force and orientation, while
conformational  flexibility  interferes  both  in  the  way  the
molecules are packed inside the crystals and in the spatial
orientation of the molecule (15,16).
Figure  3.  Comparison  between  the  diffractograms  of  active
pharmaceutical ingredients of tenoxicam and RS, obtained using
the Siemens®  Diffractometer, model D-5000, with λCuCuKα radiation
(1.5409 Å) and power of 40 kV and 25 mA.
X-Ray Diffraction
Tenoxicam polymorphs preparations 
The  crystalline  structure  of  the  standard  tenoxicam
(Changzhou  Hubin  Medicine  Raw  Materials  Co.  Ltd,
Changzhou,  China)   presents  a  form  III  crystallographic
structure  according  to  data  from  the  literature  (11,17).
Different  conditions  for  obtaining  polymorphic  forms  of
tenoxicam (forms I, II, III and IV) were applied according to
Cantera et al. (2002) (11). However the different preparation
processes  of  tenoxicam  polymorphs  did  not  lead  to
modifications  in  the  original  crystalline  structure  of  this
drug.  The  main  peaks  in  the  standard  tenoxicam
diffractogram  at   8.12°;  10.98°;  11.04°;  12.86°;  14.64°;
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14.96°;  16.16°;  16.84°;  16.88°;  17.56°;  18.7°;  19.62°;
21.94°;  23.46°;  24.3°;  25.54°;  28.52°;  28.52°;  29.58° and
30.74° 2θ), with speed of 0.02°/1s, using an energy of 40 kV and presented positions similar to the peaks found in
the  diffractograms  of  forms  I,  II,  III  and  IV,  with  close
interplanar distances (values of  d) between the three main
peaks (Figure 2). Therefore, the addition of different solvent
in  samples  of  standard  tenoxicam  under  the  conditions
proposed by Cantera,  Leza and Bachiller  (2002)  (11),  did
not promote significant changes in the crystalline structure
(form III).  This  information was also corroborated  by the
results  previous obtained by Bolla  et.  al.  (2013)  (18) and
Patel et. al. (2012) (17) who, based on the methodologies of
Cantera et. al. (2002) (11), also only obtained form III. 
Figure  2. Comparison  of  the  diffractograms  of  the  crystalline
structures forms I, II, III and IV to tenoxicam RS, using a Siemens
® Diffractometer model D-5000, with a λCuCuKα radiation (1.5409 Å)
and power of 40 kV and 25 mA.
Analysis  of  the  active  pharmaceutical  ingredients  of
tenoxicam 
The peaks present in the active ingredient GTE1, STE2 and
NTE3 evaluated present positions similar to those presented
by  standard  tenoxicam  at  8.12°;  10.98°;  11.04°;  12.86°;
14.64°;  14.96°;  16.16°;  16.84°;  16.88°;  17.56°;  18.7°;
19.62°; 21.94°; 23.46°; 24.3°; 25.54°; 28.52°; 28.52°; 29.58°
and 30.74 2θ), with speed of 0.02°/1s, using an energy of 40 kV and (Figure 3),  configuring the same crystalline
form.  Factors  such  as  nature  and  concentration  of  the
solvent, cooling velocity, time and temperature involved in
the  synthesis  of  an  active  ingredient  may  influence  the
formation of distinct crystalline structures (19).
Therefore, although they are of completely different origins,
the active pharmaceutical ingredients of tenoxicam (GTE1,
STE2 and NTE3) from different pharmaceutical  industries
presented  a  crystalline  structure  similar  to  the  standard
tenoxicam (form III). 
Analysis of the tenoxicam tablets
Figure 4 shows the evaluation of the simulated samples of
the tenoxicam tablets  by XRD. The diffractograms of  the
simulated samples of pharmaceutical products VTE0, RT1,
ETE2 and MTE3 are found to present the three most intense
peaks with very close 2θ), with speed of 0.02°/1s, using an energy of 40 kV and positions (the arrows indicate the
highest intensity peaks).  
Figure  4. Comparison  between  the  diffractograms  of  simulated
samples  of  the  tenoxicam  tablets  obtained  using  the  Siemens®
Diffractometer,  model  D-5000,  with  λCuCuKα radiation  (1.5409 Å)
and power of 40 kV and 25 mA.
When excluding the peaks corresponding to the excipients
from the evaluation, and evaluating those that correspond to
the  drug  tenoxicam  (Figure  5),  it  is  seen  that  there  are
modifications in the intensities and small alterations in the
position of the peaks of crystalline structures belonging to
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the compounds VTE0, RT1, ETE2 and MTE3 in relation to
the peaks of standard tenoxicam positioned at 8.12°; 10.98°;
11.04°;  12.86°;  14.64°;  14.96°;  16.16°;  16.84°;  16.88°;
17.56°; 18.7°; 19.62°; 21.94°; 23.46°; 24.3°; 25.54°; 28.52°;
28.52°; 29.58° and 30.74° 2θ), with speed of 0.02°/1s, using an energy of 40 kV and. 
The  shifts  in  the  positions  of  the  peaks  (20)  in  the  of
tenoxicam  tablets  (Figure  5)  are  possibly  the  result  of
transformations induced by processing  (PIT)  (7).  Although
the industrial processes may cause changes in the crystalline
structure  of  pharmaceutical  compounds  (8),  these
procedures were unable to form the new crystalline phase in
tenoxicam,  present  in  the  pharmaceutical  specialties
evaluated, since no formation of new peaks or subtraction of
those characteristic of the drug is observed, maintaining the
form III structures. In this way, the crystalline structure of
tenoxicam,  form III,  proved to  be  stable  during  the  drug
production process.  A similar result was evidenced by the
XRD  technique  for  risperidone  which  maintained  its
crystalline  structure  (polymorph A)  without  modifications
after undergoing industrial processing (20).
Figure  5. Comparison  between  the  diffractograms  of  the
pharmaceutical specialties and RS obtained using the Siemens  ®
Diffractometer,  model  D-5000,  with λCuCuKα radiation (1.5409 Å)
and power of 40 kV and 25 mA.
IR Spectrophotometry
Tenoxicam polymorphs preparations 
The absorption frequencies of the main IR bands and their
respective attributions for tenoxicam are described in Table
1  (21). Considering the absorption frequencies of the main
bands of tenoxicam in IR (Table 1) and the spectra of the
crystalline structures (form I, II, III and IV), and standard
tenoxicam  (Figure  6),  there  is  a  similarity  between  the
spectra  with  an  absence  of  alterations  on  the  IR  bands.  
The polymorphism causes shifts in the characteristic bands
of the substances resulting from the different intermolecular
interactions of each crystalline structure  (6). This does not
occur  with  the  samples  prepared  according  to  the
methodology of Cantera, Leza and Bachiller (2002) (11).
Table 1. Absorption frequencies of the main IR bands and their








C-H aromatics 3100 – 3000 3064
Vibration of axial 
deformation of C=O 
in secondary amides
1640 1634




2000 – 1600 1594
Vibration of angular 
deformation of N-H 
in secondary amides
1570 – 1515 1555
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1420 – 1330 13821322
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deformation of C-O 
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1200 – 1000
(one strong band) 1146
Axial deformation of
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alicyclic ring of five 
or six atoms
1085 – 1050 10841037
Figure 6. Spectrum in the IR (600 to 4000 cm-1) of the crystalline
forms  of  tenoxicam  obtained  using  the  Perkin  Elmer®
Spectrophotometer model FT-IR Spectrum BX, with an accessory
for attenuated total reflectance (ATR).
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Analysis  of  the  active  pharmaceutical  ingredients  of
tenoxicam 
Figure  7  records  the  IR  spectrum  of  the  active
pharmaceutical  ingredients  of  tenoxicam,  where  a  similar
spectral  profile  is  seen between the active pharmaceutical
ingredients of tenoxicam called GTE1, STE2 and NTE3 and
standard tenoxicam. No shifts are seen in the characteristic
bands,  a  peculiarity  of  polymorphism  (6), since  the
absorption bands expected for the tenoxicam molecule are
present in the samples, with bands at 1,634 cm-1 (vibration
of axial deformation of C=O in secondary amides),  1,594
cm-1 (weak bands of combination and harmonics between C-
H), 1,382 cm-1 (vibration of angular deformation on plane O-
H),  1,146 cm-1  (vibration  of  axial  deformation  of  C-O in
alcohols)  and  1,084  cm-1   (axial  deformation  of  C-O  of
secondary  alcohols,  with an alicicyclic  ring of five or six
atoms) (21).
Figure  7. IR  spectrum  IV  (600  to  4000  cm-1)  for  the
pharmaceutical ingredients of tenoxicam obtained using a Perkin
Elmer®  Spectrophotometer  model  FT-IR  Spectrum  BX  with  an
accessory for attenuated total reflectance (ATR). 
Dissolution Profile
Analysis  of  the  active  pharmaceutical  ingredients  of
tenoxicam 
Considering that solid substances may undergo changes in
their crystalline states due to the compaction to which they
are  submitted,  it  was  decided  to  dissolve  the  active
ingredients in powder form instead of intrinsic dissolution,
which  requires  compression  of  the  solid  material  to  be
analyzed. The modification of the solid form of the sample
due to the compression used would invalidate the intrinsic
dissolution assay (3). Table 2 and Figure 8 show the results
obtained  in  the  dissolution  profiles  of  pharmaceutical
ingredients GTE1, STE2 and NTE3 in powder form. In the
dissolution profiles it is seen that within 30 minutes all the
active pharmaceutical  ingredients  GTE1,  STE2 and NTE3
are dissolved, with about 75% dissolution, and no significant
difference between the dissolution profiles evaluated.
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Figure 8. Graphic representation of the particulate dissolution of four tenoxicam raw material suppliers represented by the acronyms GTE1,
STE2 and NTE3.
Table 3. Mean results obtained in the study of the dissolution profile of the tenoxicam tablets at different laboratories at times 2, 5, 10, 15,
20 and 25 minutes.a
aValues represent the mean of 12 determinations.
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Analysis of the tenoxicam tablets
The mean results referring to the dissolution profile of the
four pharmaceutical specialties are described in Table 3 and
graphically represented in Figure 9. The DE% obtained from
the areas under the curves (AUC) between 0 and 50 minutes
and the total  area  of  the rectangle  (ASCTR)  for  the active
pharmaceutical ingredients of tenoxicam presented values of
60.30% for GTE1, 60.70% for STE2 and 72.34% for NTE3.
The analysis of variance (ANOVA) showed that there was
no  significant  statistical  difference  between  the  active
pharmaceutical  ingredients regarding dissolution efficiency
(Fcal =  5.40;  p  <  0.01).
The dissolution profiles of the active ingredients evaluated,
GTE1, STE2 and NTE3 present similar dissolution profiles,
possibly  because  they  have  the  same crystalline  structure
(form III), with a similar crystallinity index.   
Although the industrial processes may cause changes in the
crystalline  structure  of  pharmaceutical  compounds,
tenoxicam in different active ingredients presented the same
crystalline  structure  (form  III).  Although  different
dissolution velocities occur between the active ingredients,
their release profile was not compromised.
According  to  the  data  presented,  the  tenoxicam  tablets
evaluated had similar profiles to each other, releasing over
85% of the drug in 15 minutes.
Table  4  shows  the  values  of  f1 and  f2 of  the  tenoxicam
tablets VTE0, RTE1, ETE2 and MTE3. Considering that the
values of f1 should be between 0 and 15 and f2 between 50
and  100,(22) the  results  indicate  differences  between  the
pharmaceutical  specialties.  The dissolution  profiles  of  the
finished products VTE0, RTE1 and ETE2 are similar, while
product MTE3 is different from these, with f1 values above
what the specification (23.95; 22.07) and f2 values below it
(32.86; 42.36; 34.27).
Table  4. Values  of  f1  and  f2  resulting  from  the  comparisons
between the tenoxicam tablets.
VTE0 RTE1 ETE2 MTE3
f1 f2 f1 f2 f1 f2 f1
VTE0 11.81 51.88 4.82 68.59 23.95 32.86
RTE1 11.81 51.88 10.45 51.93 13.77 42.36
ETE2 4.82 68.59 10.45 51.93 22.07 34.27
MTE3 23.95 32.86 13.77 42.36 22.07 34.27
When applying the dependent mathematical models it was
found  that  the  kinetics  of  tenoxicam  release  from  the
formulations  followed  zero  order  kinetics.  The  graphics
generated by the zero order kinetics equation for the samples
called  VTE0,  RTE1,  ETE2  and  MTE3  produced
determination coefficients (R2) superior to those calculated
by  the  first  order  model.  Besides,  when  evaluating  the
kinetic models tested, the o MSC (Model Selection Criteria)
assigned higher values to the zero order model; Therefore
the zero order model describe the tenoxicam release profile
more appropriately, since the most appropriate model is the
one which presents a value of R2 close to one (Table 5).
Table  5. Determination  coefficients  (R2)  and  values  of  MSC
obtained  from  the  dissolution  profiles  of  tablets  containing




























Based  on  the  zero  order  kinetic  model,  which  was
approached  most  closely  by  the  release  mechanism  of
tenoxicam, the release constant  (k),  the half-life (t50%) and
the amount  released  in  25  minutes  (Q25)  were  calculated.
Table 6 shows that the specialties VTE0, RTE1, ETE2 and
MTE3 presented very similar amounts of drug released in 25
minutes, and specialty MTE3 exhibited the shortest half-life
among  the  formulations,  indicating  better  product
performance. 
Dissolution  efficient  DE  (%)  for  the  different  tenoxicam
tablets was also determined (Table 6). This parameter was
obtained from the areas under the curves (AUC) between 0
and 25 minutes, and the total area of the rectangle (ASCTR).
Among  the  pharmaceutical  specialties  of  tenoxicam
evaluated,  the MTE3 presentation exhibited a DE% value
close to 100%. Analysis of variance (ANOVA) showed that
there  is  a  significant  statistical  difference  between  the
pharmaceutical  specialties  regarding  the  values  of  DE  %
(Fcal = 66.55; p < 0.01). According to the values obtained for
the Tukey test, multiple comparison of means and p < 0.01,
it  was found that  the tenoxicam tablet  MTE3 presented  a
significant  statistical  difference  between  the  formulations
evaluated,  thus  reflecting  a  difference  in  its  dissolution
profile in relation to the other pharmaceutical specialties.
Table 6. Release constant (k),  half life time (t50%) and amount
released in 25 minutes (Q25), according to the equation adjusted




























The tenoxicam tablets evaluated  VTE0,  RTE1, ETE2 and
MTE3 presented  qualitatively  similar  dissolution  profiles,
since the mathematical model for the best fit of the data was
the same for all formulations. However, applying the kinetic
model  identified  differences  regarding  the  half  life  and
dissolution velocity, especially for the commercial product
MTE3.  This  result  corroborated  the  data  obtained  by  the
independent model f1 and f2, which indicated a difference in
the  dissolution  profile  for  this  same  pharmaceutical
specialty.
Different  methods used for comparison purposes can give
rise to different results. This is because some parameters are
more  discriminating  for  differentiating  pharmaceutical
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specialties.(23)  However, the results obtained  by comparing
the independent models  f1 and  f2, kinetic parameters, and
values of dissolution efficiency, proved concordant with the
medication MTE3. 
Although the  tenoxicam tablets  have  the  same crystalline
structure, they presented different DE%. The pharmaceutical
tablets VTE0, RTE1 e ETE2 presented a slower dissolution
and a smaller DE%, possibly due to the higher crystallinity
index  present  in  their  chemical  structures.  The  faster
dissolution and higher DE% of the pharmaceutical product
MTE3 may possibly be the result of the lower crystallinity
index. The substances with a lower crystallinity index, are
mostly  more  soluble  than  materials  with  a  higher
crystallinity index,(24) which fact has possibly influenced the
results expounded above. 
Conclusions
Polymorphism  affects  physical,  chemical  and
biopharmaceutical properties, both for active ingredients and
for  pharmaceutical  formulations,  and  it  is  a  relevant
physicochemical parameter for the pharmaceutical industry.
The  analyses  performed  showed  that  the  active
pharmaceutical  ingredients  and  the  pharmaceutical  tablets
available in the market, when submitted to analysis by XRD
presented similar crystalline structures (form III). Although
the  pharmaceutical  formulations  present  different
dissolution  profiles,  the  industrial  process  to  which
tenoxicam was submitted did not have a significant impact
on its crystalline structure, considering that the quality of the
pharmaceutical products was maintained. 
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